The University of Oxford and the pharmaceutical AstraZeneca (AZ) are working on adapting their coronavirus vaccine to be effective against the omicron variant, according to the “Financial Times” (FT) newspaper.
In this way, Oxford-AZ joins other laboratories that are studying the possibility of adapting their preparations to this new variant, after experts warned that current vaccines would not be as effective against omicron.
“Together with our AstraZeneca partners, we have taken preliminary steps to produce an updated vaccine should it be needed,” Oxford research group leader Sandy Douglas told the FT.
The researchers, according to the journal, estimate that the development of this vaccine may take about a hundred days.
These studies come to light as many European countries have re-imposed strong restrictions due to the rapid spread of the omicron variant, which, according to scientists, is much more contagious than the delta.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
